Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 16, Issue 1, 2013, Pages 37-46

  Gibbons, Andrew Stuart ^a   Scarr, Elizabeth ^a   Boer, Simone ^a   Money, Tammie ^a   Jeon, Won Je ^a   Felder, Chris ^b   Dean, Brian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Acetylcholine; muscarinic receptors; post mortem cortex; schizophrenia

Indexed keywords

4DAMP H 3; AF DX 386 H 3; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; PIRENZEPINE H 3; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; MOUSE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANIMALS; CEREBRAL CORTEX; COHORT STUDIES; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PIRENZEPINE; PROTEIN BINDING; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84871497691     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000028     Document Type: Article

References (52)

1. Allard WJ, Sigal IS, Dixon RA (1987). Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor. Nucleic Acids Research 15, 10604.
2. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, et al. (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nature Neuroscience 6, 51-58.
3. Bush G, Luu P, Posner MI (2000). Cognitive and emotional influences in anterior cingulate cortex. Trends in Cognitive Science 4, 215-222.
4. Cawley TA, Shickley TJ, Ruggieri MR, Luthin GR (1993). Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors. Journal of Pharmacology and Experimental Therapeutics 267, 134-139.
5. Conn PJ, Jones CK, Lindsley CW (2009). Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacological Science 30, 148-155.
6. Cook RD, Weisberg S (2011). Applied Regression Including Computing and Graphics. Hoboken: Wiley.
7. Crook JM, Dean B, Pavey G, Copolov D (1999). The binding of [3H]AF-DX 384 is reduced in the caudateputamen of subjects with schizophrenia. Life Sciences 64, 1761-1771.
8. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001). Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. American Journal of Psychiatry 158, 918-925.
9. d'Agostino RB, Belanger A, d'Agostino Jr. RB (1990). A suggestion for using powerful and informative tests of normality. American Statistician 44, 316-321.
10. Dean B (2004). M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology 29, 1583-1584.
11. Dean B, Crook JM, Opeskin K, Hill C, et al. (1996). The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Molecular Psychiatry 1, 54-58.
12. Dean B, McLeod M, Keriakous D, McKenzie J, et al. (2002). Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 7, 1083-1091.
13. Dean B, Pavey G, Chai SW, Mendelsohn FAO (1999). The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. In : Dean B, Hyde TM, Kleinman J (Ed.), The Use of CNS Autopsy Tissue in Psychiatric Research : a Practical Guide (pp. 67-83). Sydney: Gordon & Breach Science Publishers.
14. Dean B, Soulby A, Evin GM, Scarr E (2008). Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophrenia Research 106, 229-236.
15. Deng C, Huang XF (2005). Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. Journal of Neuroscience Research 81, 883-890.
16. Dorje F, Wess J, Lambrecht G, Tacke R, et al. (1991). Antagonist binding profiles of five cloned human muscarinic receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 256, 727-733.
17. Felder CC, Porter AC, Skillman TL, Zhang L, et al. (2001). Elucidating the role of muscarinic receptors in psychosis. Life Sciences 68, 2605-2613.
18. Ferrer I, Santpere G, Arzberger T, Bell J, et al. (2007). Brain protein preservation largely depends on the postmortem storage temperature : implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. Journal of Neuropathology and Experimental Neurology 66, 35-46.
19. Garey LJ (1999). Brodmann's Localisation in the Cerebral Cortex. London: Imperial College Press.
20. Gibbons AS, Scarr E, McLean C, Sundram S, et al. (2009). Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. Journal of Affective Disorders 116, 184-191.
21. Gomeza J, Zhang L, Kostenis E, Felder C, et al. (1999). Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proceedings of the National Academy of Sciences USA 96, 10483-10488.
22. Greba Q, Munro LJ, Kokkinidis L (2000). The involvement of ventral tegmental area cholinergic muscarinic receptors in classically conditioned fear expression as measured with fear-potentiated startle. Brain Research 870, 135-141.
23. Hamilton SE, Loose MD, Qi M, Levey AI, et al. (1997). Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proceedings of the National Academy of Sciences USA 94, 13311-13316.
24. Han M, Newell K, Zavitsanou K, Deng C, et al. (2008). Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research 86, 457-464.
25. Hill C, Keks N, Roberts S, Opeskin K, et al. (1996). Problem of diagnosis in postmortem brain studies of schizophrenia. American Journal of Psychiatry 153, 533-537.
26. Insel TR (2009). Disruptive insights in psychiatry : transforming a clinical discipline. Journal of Clinical Investigation 119, 700-705.
27. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, et al. (1995). Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Molecular Brain Research 28, 311-318.
28. Koechlin E (2011). Frontal pole function: what is specifically human? Trends in Cognitive Science 15, 241.
29. Koechlin E, Ody C, Kouneiher F (2003). The architecture of cognitive control in the human prefrontal cortex. Science 302, 1181-1185.
30. McCullagh P, Neider JA (1989). Generalised Linear Models. London: Chapman and Hall.
31. Paus T (2001). Primate anterior cingulate cortex : where motor control, drive and cognition interface. Nature Review Neuroscience 2, 417-424.
32. Pavey GM, Copolov DL, Dean B (2002). High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding. Journal of Neuroscience Methods 116, 157-163.
33. Porter AC, Bymaster FP, DeLapp NW, Yamada M, et al. (2002). M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Research 944, 82-89.
34. Pradidarcheep W, Labruyere WT, Dabhoiwala NF, Lamers WH (2008). Lack of specificity of commercially available antisera : better specifications needed. Journal of Histochemistry and Cytochemistry 56, 1099-1111.
35. Raedler TJ, Bymaster FP, Tandon R, Copolov D, et al. (2007). Towards a muscarinic hypothesis of schizophrenia. Molecular Psychiatry 12, 232-246.
36. Raedler TJ, Knable MB, Jones DW, Urbina RA, et al. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. American Journal of Psychiatry 160, 118-127.
37. Roberts SB, Hill CA, Dean B, Keks NA, et al. (1998). Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Australian and New Zealand Journal of Psychiatry 32, 73-76.
38. Salah-Uddin H, Scarr E, Pavey G, Harris K, et al. (2009). Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology 34, 2156-2166.
39. Sams AG, Hentzer M, Mikkelsen GK, Larsen K, et al. (2010). Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-p henylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. Journal of Medicinal Chemistry 53, 6386-6397.
40. Sauerberg P, Olesen PH, Nielsen S, Treppendahl S, et al. (1992). Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. Journal of Medicinal Chemistry 35, 2274-2283.
41. Scarr E, Cowie TF, Kanellakis S, Sundram S, et al. (2009). Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Molecular Psychiatry 14, 1017-1023.
42. Scarr E, Dean B (2008). Muscarinic receptors : do they have a role in the pathology and treatment of schizophrenia? Journal of Neurochemistry 107, 1188-1195.
43. Shapiro RA, Scherer NM, Habecker BA, Subers EM, et al. (1988). Isolation, sequence, and functional expression of the mouse M1 muscarinic acetylcholine receptor gene. Journal of Biological Chemistry 263, 18397-18403.
44. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, et al. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. American Journal of Psychiatry 165, 1033-1039.
45. Shideler KK, Yan J (2010). M1 muscarinic receptor for the development of auditory cortical function. Molecular Brain 3, 29.
46. Stan AD, Ghose S, Gao XM, Roberts RC, et al. (2006). Human postmortem tissue : what quality markers matter? Brain Research 1123, 1-11.
47. Tamminga CA (2008). Accelerating new knowledge in schizophrenia. American Journal of Psychiatry 165, 949-951.
48. Tecle H, Schwarz RD, Barrett SD, Callahan MJ, et al. (2000). CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharmaceutica Acta Helvetiae 74, 141-148.
49. Thomas DR, Dada A, Jones GA, Deisz RA, et al. (2010). N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor. Neuropharmacology 58, 1206-1214.
50. Wevers A (2011). Localisation of pre-and postsynaptic cholinergic markers in the human brain. Behavioral Brain Research 221, 341-355.
51. Zavitsanou K, Katsifis A, Mattner F, Huang XF (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29, 619-625.
52. Zavitsanou K, Katsifis A, Yu Y, Huang XF (2005). M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Research Bulletin 65, 397-403.